Jacob Asset Management of New York’s Heron Therapeutics HRTX Stock Holding History

Jacob Asset Management of New York’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$337K	Buy	327,450 +50,435	+18%	+$71.8K	0.48%	52
2023 Q2	$321K	Sell	277,015 -49,642	-15%	-$88.5K	0.36%	54
2023 Q1	$493K	Buy	326,657 +59,629	+22%	+$149K	0.58%	47
2022 Q4	$668K	Buy	267,028 +27,682	+12%	+$89.2K	0.81%	38
2022 Q3	$1.01M	Buy	239,346 +58,336	+32%	+$228K	1.1%	32
2022 Q2	$505K	Buy	181,010 +43,755	+32%	+$176K	0.51%	43
2022 Q1	$785K	Buy	137,255 +76,897	+127%	+$563K	0.48%	43
2021 Q4	$551K	Sell	60,358 -2,740	-4%	-$28K	0.25%	62
2021 Q3	$675K	Buy	63,098 +21,098	+50%	+$257K	0.25%	59
2021 Q2	$652K	Buy	42,000 +20,000	+91%	+$318K	0.22%	74
2021 Q1	$357K	Hold	22,000	–	–	0.14%	74
2020 Q4	$466K	Buy	+22,000	New	+$382K	0.35%	51

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Jacob Asset Management of New York's HRTX Position: Q3 2023 in Review

Jacob Asset Management of New York increased its Heron Therapeutics (HRTX) stake by 18% in Q3 2023, buying an estimated $71.8K and bringing the position to 327,450 shares worth $337K. The position accounts for 0.48% of the portfolio, ranked #52.

Jacob Asset Management of New York first reported a position in HRTX in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.01M in Q3 2022. 141 funds tracked by Wall St. Rank hold HRTX as of Q3 2023.

Jacob Asset Management of New York held 327,450 shares of Heron Therapeutics worth $337K as of Q3 2023.
Jacob Asset Management of New York bought 50,435 Heron Therapeutics shares in Q3 2023, an estimated $71.8K.
Heron Therapeutics made up 0.48% of Jacob Asset Management of New York's portfolio in Q3 2023, its #52 holding.
Jacob Asset Management of New York first reported a position in Heron Therapeutics in Q4 2020 and has held it in 12 quarters since.
Jacob Asset Management of New York's Heron Therapeutics position peaked at $1.01M in Q3 2022.
141 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2023.

Based on Jacob Asset Management of New York's 13F filing for Q3 2023, filed 1 Nov 2023.